Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study

Nishikubo, Masashi; Shimomura, Yoshimitsu; Maruoka, Hayato; Nasu, Seiko; Nishioka, Tomomi; Sakizono, Kenji; Mitsuyuki, Satoshi; Kubo, Tomoyo; Okada, Naoki; Nakagawa, Daishi; Kamijo, Kimimori; Imoto, Hiroharu; Yamamoto, Ryusuke; Nagai, Yuya; Hiramoto, Nobuhiro; Yoshioka, Satoshi; Yonetani, Noboru; Matsushita, Akiko; Miyakoshi, Chisato; Doi, Asako; Ishikawa, Takayuki

doi:10.1016/j.jiac.2022.11.010

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After applying the eligibility criteria, 102 studies remained, forming the evidentiary basis for the guideline recommendations: 24 systematic reviews, 11, 14 RCTs, 6,[44][45][46][47][48][49][50][51][52][53][54][55][56] and 64 nonrandomized studies. [85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120] The ...…”

Section: Characteristics Of Studies Identified In the Literature Searchmentioning

confidence: 99%

“…Humoral responses are subdued in the first year after HSCT, and this effect is more pronounced with advanced age, concurrent lymphopenia, GVHD, underlying non-Hodgkin lymphoma, and ongoing immunosuppressive or corticosteroid use. 57,95,99 Evidence also indicates that seroconversion is improved with additional primary and booster doses to address poor initial response and accelerated antibody decay in HSCT recipients. 148 A substantial subset of humoral nonresponders can mount virus-specific cellular immune responses after vaccination.…”

Section: Covid-19 Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination of Adults With Cancer: ASCO Guideline

Kamboj,

Bohlke,

Baptiste

et al. 2024

JCO

View full text Add to dashboard Cite

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE To guide the vaccination of adults with solid tumors or hematologic malignancies. METHODS A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and nonrandomized studies on the efficacy and safety of vaccines used by adults with cancer or their household contacts. This review builds on a 2013 guideline by the Infectious Disease Society of America. PubMed and the Cochrane Library were searched from January 1, 2013, to February 16, 2023. ASCO convened an Expert Panel to review the evidence and formulate recommendations. RESULTS A total of 102 publications were included in the systematic review: 24 systematic reviews, 14 RCTs, and 64 nonrandomized studies. The largest body of evidence addressed COVID-19 vaccines. RECOMMENDATIONS The goal of vaccination is to limit the severity of infection and prevent infection where feasible. Optimizing vaccination status should be considered a key element in the care of patients with cancer. This approach includes the documentation of vaccination status at the time of the first patient visit; timely provision of recommended vaccines; and appropriate revaccination after hematopoietic stem-cell transplantation, chimeric antigen receptor T-cell therapy, or B-cell–depleting therapy. Active interaction and coordination among healthcare providers, including primary care practitioners, pharmacists, and nursing team members, are needed. Vaccination of household contacts will enhance protection for patients with cancer. Some vaccination and revaccination plans for patients with cancer may be affected by the underlying immune status and the anticancer therapy received. As a result, vaccine strategies may differ from the vaccine recommendations for the general healthy adult population vaccine. Additional information is available at www.asco.org/supportive-care-guidelines .

show abstract

Section: Characteristics Of Studies Identified In the Literature Searchmentioning

confidence: 99%

Section: Covid-19 Vaccinesmentioning

confidence: 99%

Vaccination of Adults With Cancer: ASCO Guideline

Kamboj,

Bohlke,

Baptiste

et al. 2024

JCO

View full text Add to dashboard Cite

show abstract

The booster dose of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral and clinical response and serological conversion predictors

Majcherek,

Matkowska-Kocjan,

Szymczak

et al. 2023

Acta Oncologica

View full text Add to dashboard Cite

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-Analysis Using GRADE

Kavikondala,

Haeussler,

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Aim: Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose COVID-19 vaccines may offer increased immunogenicity. Materials & methods: A pairwise meta-analysis of 98 studies reporting comparisons of mRNA-1273 (50 or 100 mcg/dose) and BNT162b2 (30 mcg/dose) in IC adults was performed. Outcomes were seroconversion, total and neutralizing antibody titers, and cellular immune responses. Results: mRNA-1273 was associated with a significantly higher seroconversion likelihood (relative risk, 1.11 [95% CI, 1.08, 1.14]; P<0.0001; I2=66.8%) and higher total antibody titers (relative increase, 50.45% [95% CI, 34.63%, 66.28%]; P<0.0001; I2=89.5%) versus BNT162b2. mRNA-1273 elicited higher but statistically nonsignificant relative increases in neutralizing antibody titers and cellular immune responses versus BNT162b2. Conclusion: Higher-dose mRNA-1273 had increased immunogenicity versus BNT162b2 in IC patients.

show abstract

Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study

Cited by 4 publications

References 26 publications

Vaccination of Adults With Cancer: ASCO Guideline

Vaccination of Adults With Cancer: ASCO Guideline

The booster dose of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral and clinical response and serological conversion predictors

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-Analysis Using GRADE

Contact Info

Product

Resources

About